<div id="readability-page-1">Korro Bio (KRRO) shares fell following results from its early-stage clinical trial of KRRO-110, aimed at treating patients with alpha-1 antitrypsin deficiency.The trial revealed that KRRO-110 failed to meet the expected levels of functional protein after a single dose. Although the treatment did produce some functional protein, the amounts were bel...</div>

KRRO

<p>Korro Bio 的股票下跌，因为 KRRO-110 试验未能达到预期的α-1 抗胰蛋白酶缺乏症治疗所需的蛋白质水平，尽管产生了一些功能性蛋白质</p>

Korro Bio 的股票在 KRRO-110 早期试验未能达到预期后下跌